Amgen

We are all different, yet we have this in common: our mission to serve patients. This sense of shared purpose is key to our becoming one of the world’s leading biotechnology companies. It guides us as we continue to launch new medicines and reach millions of patients worldwide.

We live the mission.

We win together.

We thrive on continual challenge.

Our team of 27,000+ scientists and professionals worldwide bring distinct perspectives and experiences to all we do. We leverage our global talent to achieve together—to research, manufacture and deliver ever-better products and greater depth to our mission.

At Amgen, there is a strong correlation between our high level of diversity and performance. Because addressing issues with a wider range of perspectives and approaches leads to more creative problem-solving. Together, we’re transforming the promise of science and biotechnology into therapies that have the power to restore health.

Connect with us to explore how you can Win, Live, and Thrive at Amgen.

AWARDS

Corporate Headquarters
One Amgen Center Drive
Thousand Oaks, CA 91320

Tel: 805-447-1000

Visit website

Email Us

LIVE. WIN. THRIVE.

We know an idea—any idea—can blossom into a lifesaving treatment. That’s why we dare to ask the questions most people won’t. Join us in pushing biotechnology.

Join Us

Employee Testimonials

“Amgen fosters a culture of innovation, with a science-based risk approach, centered in the benefit of our patients and powered by the diversity of our staff.”

Jorge D.
Porcess Scientific Director
Juncos, PR
“Cultivate your curiosity and continue to learn at Amgen — grow daily and explore career opportunities that align with your competencies and motivation”

Fernando F.
Executive Director Plant Manager
Rhode Island, US
“Working at Amgen, as Specialist Quality Control gives me the opportunity to work with Amgen products in benefit of the patients. Using my knowledge in science and share my diversity with my peers, is the best experience I have as part of the Amgen family.”

Niria R.
Specialist Quality Control
Juncos, PR

Diversity and Inclusion
Benefits
Community Investment
Awards and Accolades

Serving patients across the globe requires a global team. We continue building a diverse workforce that reflects the needs of those they serve, bringing with them innovative ideas that can push biotechnology forward.

Learn More

We offer more than benefits. Our Total Rewards Program secures the long-term financial, physical and overall well-being of you and your family. Among leading biotechnology and pharmaceutical leaders, we stand among the very best.

Learn More

Through Amgen Volunteers, you can dedicate eight hours to participating organizations of your choice. This along with matching employee donations to charities and our diverse corporate giving initiatives are just some ways you can make meaningful contributions as a global citizen

Learn More

Amgen is proud of the achievements we have realized as a mission-driven team—particularly the accolades we have earned as an employer. You can find our teams named in respected lists including Forbes, Fast Company and more.

Learn More

NEWS

Drug Development

AstraZeneca, Amgen Breathing Easier with Optimistic Phase III Asthma Drug Results

After announcing a successful primary endpoint in November, AstraZeneca and Amgen presented the full data on their severe asthma antibody candidate on Friday.

February 26, 2021

3 min read

Kate Goodwin

Drug Development

Amgen Submits Supplemental NDA for Mild-to-Moderate Psoriasis Drug Otezla

Otezla, an oral small-molecule inhibitor of phosphodiesterase 4 (PDE4) directed for cyclic adenosine monophosphate (cAMP), may indirectly modulate inflammatory mediators in certain conditions, but the specific underlying mechanisms are not clearly understood.

February 22, 2021

2 min read

Brandon May

Biotech Beach

Agilent Technologies is Most Sustainable Health Care Company, Survey Shows

Agilent is one of seven health care companies to make the fourth annual list of 100 companies compiled by the publication.

February 19, 2021

3 min read

Alex Keown

FDA

Amgen Moves One Step Closer to First Approved KRAS Inhibitor for Lung Cancer

The U.S. FDA granted Amgen Priority Review for sotorasib for patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), after at least one previous systemic therapy.

February 17, 2021

2 min read

Mark Terry

Policy

Court Rules Against Amgen PCSK9 Patent Claims Against Sanofi and Regeneron

A long-running court battle over PCSK9 antibodies between Amgen and Sanofi and Regeneron has come to an end, for now at least.

February 12, 2021

2 min read

Alex Keown

Bio NC

Clinical Catch-Up: February 1 – February 5

It was a busy week for clinical trial updates. Here’s a look.

February 5, 2021

11 min read

Mark Terry

Business

Amgen’s Sales Team Faces Layoffs, Hundreds of Jobs Cut at Headquarters

Amgen is in the process of eliminating hundreds of U.S. jobs, the majority of which are centered on the company’s sales team, according to a recent sales call.

February 4, 2021

3 min read

Brandon May

Christopher Polk/Getty Images for International Me

Drug Development

Amgen Q4 Report: Five Halted or Killed Cancer Programs, Revenue Up 7%

Amgen released its fourth-quarter and full-year 2020 results today and although there was good news financially, there was also news of five cancer programs that have either been halted or abandoned.

February 3, 2021

3 min read

Mark Terry

Drug Development

Amgen Racks Up Success in Phase II Lung Cancer Trial

Amgen announced data from the Phase II cohort of the CodeBreaK 100 trial of sotorasib (AMG 510) in 126 patients with KRAS G12C-mutated advanced non-small cell lung cancer.

January 29, 2021

3 min read

Mark Terry

JOBS